523 related articles for article (PubMed ID: 26408528)
1. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.
German CL; Baladi MG; McFadden LM; Hanson GR; Fleckenstein AE
Pharmacol Rev; 2015 Oct; 67(4):1005-24. PubMed ID: 26408528
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters.
Mulvihill KG
Neurochem Int; 2019 Jan; 122():94-105. PubMed ID: 30465801
[TBL] [Abstract][Full Text] [Related]
3. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
[TBL] [Abstract][Full Text] [Related]
4. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants.
Jayanthi LD; Ramamoorthy S
AAPS J; 2005 Oct; 7(3):E728-38. PubMed ID: 16353949
[TBL] [Abstract][Full Text] [Related]
5. Role of monoamine transporters in mediating psychostimulant effects.
Riddle EL; Fleckenstein AE; Hanson GR
AAPS J; 2005 Dec; 7(4):E847-51. PubMed ID: 16594636
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in dopamine- and vesicular monoamine-transporter functions.
Dluzen DE; McDermott JL
Ann N Y Acad Sci; 2008 Oct; 1139():140-50. PubMed ID: 18991858
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
9. Monoamine transporter as a target molecule for psychostimulants.
Sora I; Li B; Fumushima S; Fukui A; Arime Y; Kasahara Y; Tomita H; Ikeda K
Int Rev Neurobiol; 2009; 85():29-33. PubMed ID: 19607959
[TBL] [Abstract][Full Text] [Related]
10. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
Fleckenstein AE; Volz TJ; Hanson GR
Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):133-8. PubMed ID: 18662707
[TBL] [Abstract][Full Text] [Related]
11. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
Bernstein AI; Stout KA; Miller GW
J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
[TBL] [Abstract][Full Text] [Related]
12. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
13. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.
Vergo S; Johansen JL; Leist M; Lotharius J
Brain Res; 2007 Dec; 1185():18-32. PubMed ID: 18028884
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line.
Schmitt M; Dehay B; Bezard E; Garcia-Ladona FJ
Synapse; 2016 Mar; 70(3):71-86. PubMed ID: 26695835
[TBL] [Abstract][Full Text] [Related]
15. Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders.
Gowrishankar R; Hahn MK; Blakely RD
Neurochem Int; 2014 Jul; 73():42-8. PubMed ID: 24231471
[TBL] [Abstract][Full Text] [Related]
16. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
17. A splice variant of the Drosophila vesicular monoamine transporter contains a conserved trafficking domain and functions in the storage of dopamine, serotonin, and octopamine.
Greer CL; Grygoruk A; Patton DE; Ley B; Romero-Calderon R; Chang HY; Houshyar R; Bainton RJ; Diantonio A; Krantz DE
J Neurobiol; 2005 Sep; 64(3):239-58. PubMed ID: 15849736
[TBL] [Abstract][Full Text] [Related]
18. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277
[TBL] [Abstract][Full Text] [Related]
19. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits.
Volz TJ; Hanson GR; Fleckenstein AE
J Neurochem; 2007 May; 101(4):883-8. PubMed ID: 17250674
[TBL] [Abstract][Full Text] [Related]
20. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.
Lohr KM; Masoud ST; Salahpour A; Miller GW
Eur J Neurosci; 2017 Jan; 45(1):20-33. PubMed ID: 27520881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
